Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433310 · ClinicalTrials.gov registry record · Phase 4
Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study
A Phase 4 study of Gut Microbiome and Gut Health, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06433310: Recruiting Phase 4 study of Gut Microbiome and Gut Health, sponsored by Weill Medical College of Cornell University.
NCT06433310 is a Phase 4 study of Gut Microbiome and Gut Health that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants, below the 267-participant average among 22 other Gut Microbiome trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06433310, a Phase 4 study of Gut Microbiome and Gut Health, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.
Primary Outcome
Metabolite phenylpropionic acid levels will be measured using mass spectrometry before (baseline) and after intervention
Conditions Studied
Interventions
- DRUG L-Phenylalanine 500 mg Veg Capsule product
Study Locations (1)
New York
- Belfer Research Building - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 4 |
What NCT06433310 shows while recruiting
NCT06433310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 267-participant average among 22 other Gut Microbiome trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Gut Microbiome appearing as the primary indexed condition, and to 1 intervention - of which L-Phenylalanine 500 mg Veg Capsule product is the first listed.
NCT06433310 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06433310 about?
NCT06433310 is a clinical study titled "Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study". The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.
What is the current status of trial NCT06433310?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-10-17. Estimated completion is 2027-12-31.
What conditions does trial NCT06433310 study?
This clinical trial studies the following conditions: Gut Microbiome, Gut Health, Dietary Supplement, L-Phenylalanine, Phenylpropionic Acid.
What interventions are being tested in trial NCT06433310?
The interventions under investigation include: L-Phenylalanine 500 mg Veg Capsule product (DRUG).
Who is sponsoring clinical trial NCT06433310?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433310 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gut Microbiome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06433310's enrollment target sits among peer trials
20 21st of 22 higher than 1 of 22 other Gut Microbiome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gut Microbiome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
RECRUITING · NA
-
Enhanced Nutritional Optimization in LVAD Trial
RECRUITING · NA
-
Feasibility and Potential Efficacy of Herbs and Spices for Improving Dietary Quality in College Students: A Pilot Study
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI